Biogen and Denali Therapeutics said BIIB122 failed to meet both primary and secondary endpoints in the Phase 2b LUMA study for idiopathic Parkinson's disease. The companies are discontinuing development of the experimental treatment, a setback for their neuroscience pipeline and a negative read-through for the shares.
Biogen and Denali Therapeutics said BIIB122 failed to meet both primary and secondary endpoints in the Phase 2b LUMA study for idiopathic Parkinson's disease. The companies are discontinuing development of the experimental treatment, a setback for their neuroscience pipeline and a negative read-through for the shares.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
